Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EPS (Basic) (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of EPS (Basic) data on record, last reported at -$0.3 in Q4 2024.

  • For Q4 2024, EPS (Basic) rose 47.37% year-over-year to -$0.3; the TTM value through Sep 2025 reached -$0.31, up 83.88%, while the annual FY2024 figure was -$1.58, 32.48% up from the prior year.
  • EPS (Basic) reached -$0.3 in Q4 2024 per FHTX's latest filing, up from -$0.31 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.53 in Q4 2020 and bottomed at -$3.15 in Q3 2020.
  • Average EPS (Basic) over 5 years is -$0.78, with a median of -$0.64 recorded in 2021.
  • The widest YoY moves for EPS (Basic): up 78.28% in 2021, down 130.43% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at $2.53 in 2020, then plummeted by 130.43% to -$0.77 in 2021, then grew by 10.39% to -$0.69 in 2022, then increased by 17.39% to -$0.57 in 2023, then soared by 47.37% to -$0.3 in 2024.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.3 in Q4 2024, -$0.31 in Q3 2024, and -$0.45 in Q2 2024.